Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure
- PMID: 36036745
- DOI: 10.1093/eurheartj/ehac483
Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure
Conflict of interest statement
Conflict of interest: J.H. receives salary support from T32 training grant T32HL069749. S.D.A. receives fees from Abbott, Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics, Novartis, Occlutech, Servier, and Vifor Pharma, and grant support from Abbott and Vifor Pharma. J.B. serves as a consultant to Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Berlin Cures, Boehringer Ingelheim, Bristol-Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Occlutech, Relypsa, Roche, Sanofi, SC Pharma, V-Wave Limited, and Vifor.
Comment on
-
Empagliflozin in acute myocardial infarction: the EMMY trial.Eur Heart J. 2022 Nov 1;43(41):4421-4432. doi: 10.1093/eurheartj/ehac494. Eur Heart J. 2022. PMID: 36036746 Free PMC article. Clinical Trial.
Similar articles
-
Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure.Eur Heart J. 2022 Aug 14;43(31):2994-2996. doi: 10.1093/eurheartj/ehac304. Eur Heart J. 2022. PMID: 35680380 No abstract available.
-
SGLT2 inhibitors in heart failure: insights from plasma proteomics.Eur Heart J. 2022 Dec 21;43(48):5003-5005. doi: 10.1093/eurheartj/ehac624. Eur Heart J. 2022. PMID: 36342292 No abstract available.
-
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5. Am J Med. 2018. PMID: 29309741 No abstract available.
-
Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.Am J Cardiol. 2019 Dec 15;124 Suppl 1:S20-S27. doi: 10.1016/j.amjcard.2019.10.026. Am J Cardiol. 2019. PMID: 31741436 Review.
-
Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials.J Cardiovasc Pharmacol. 2021 Jun 1;77(6):787-795. doi: 10.1097/FJC.0000000000001018. J Cardiovasc Pharmacol. 2021. PMID: 33843765
Cited by
-
Biomarkers for Heart Failure Prediction and Prevention.J Cardiovasc Dev Dis. 2023 Dec 6;10(12):488. doi: 10.3390/jcdd10120488. J Cardiovasc Dev Dis. 2023. PMID: 38132656 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical